- Conditions
- Physical Activity
- Interventions
- Accelerometer, Step goal, Consistent contexts, Inconsistent contexts
- Device · Behavioral
- Lead sponsor
- Brandeis University
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 113
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
- Interventions
- PEPRR, Pep-Pal
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Age-associated Memory Impairment
- Interventions
- Transcranial Magnetic Stimulation (TMS) Cone Coil, Transcranial Magnetic Stimulation (TMS) Sham Coil
- Device
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cognitive Change
- Interventions
- N-back, Span, Multisensory
- Behavioral
- Lead sponsor
- Northeastern University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Irvine, California • Riverside, California
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- bortezomib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cognitive Change, Processing, Visual Spatial, Inhibition (Psychology), Working Memory
- Interventions
- HUBOD, Active Comparator, Control Condition
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more
- Conditions
- Alport Syndrome
- Interventions
- BAY 3401016, Placebo
- Biological · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
- Conditions
- Waitlist Control, Experimental
- Interventions
- Youth Mental Health First Aid
- Other
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- College Park, Maryland
- Conditions
- Physical Activity, Self Efficacy, Working Adults
- Interventions
- Efficacy for Lifestyle PA, Efficacy for Work-life Balance
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 25 Years to 64 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Champaign, Illinois
- Conditions
- Recurrent Herpes Labialis
- Interventions
- Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Atrial Fibrillation
- Interventions
- BAY 3670549, Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- NG-nitro-L-arginine methyl ester (L-NAME)
- Other
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Melanoma
- Interventions
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Relapsed/Refractory Systemic Light Chain Amyloidosis
- Interventions
- Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 8
- States / cities
- Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Cognitive Change
- Interventions
- Active HD-tDCS, Sham HD-tDCS
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Interventions
- 27T51, Cemiplimab, Bevacizumab
- Other · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more
- Conditions
- Healthy, Brain Stimulation, Transcranial Direct Current Stimulation (tDCS), Cognition, Psychomotor Performance, Neurophysiology
- Interventions
- Active Transcranial Electrical Stimulation, Sham Transcranial Electrical Stimulation
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Gonorrhea, Chlamydia, Meningococcal Vaccines
- Interventions
- Trumenba Vaccine, MenACWY Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 1,307,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Young Adults
- Interventions
- working memory and attention
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin